Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer
AstraZeneca's Tagrisso (osimertinib) approved in EU for treating locally advanced, unresectable NSCLC with EGFR exon 19 deletions or exon 21 mutations, not progressed post platinum-based CRT. Tagrisso reduced disease progression/death risk by 84% vs placebo in LAURA Phase III trial. Median PFS was 39.1 months vs 5.6 months for placebo. OS results remain immature.
Highlighted Terms
Related News
Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer
AstraZeneca's Tagrisso (osimertinib) approved in EU for treating locally advanced, unresectable NSCLC with EGFR exon 19 deletions or exon 21 mutations, not progressed post platinum-based CRT. Tagrisso reduced disease progression/death risk by 84% vs placebo in LAURA Phase III trial. Median PFS was 39.1 months vs 5.6 months for placebo. OS results remain immature.